All posts tagged
How Biotech is Mastering Multiple Sclerosis: A Review
CAR-T Competition Heats Up with a New IND Approval
A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology
Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors
French Immunotherapy Partners fight against Autoimmune Disorders
The 10 Biggest Clinical Success Stories of 2016 in European Biotech
Cellectis gets paid for a first Milestone, Investors are pleased
EU approves Combo-Drug for Metastatic Colorectal Cancer
First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!
How Good was 2015 for the French Universal CAR-T Biotech?
This Swiss Biotech is Using an Ancient Virus in our Genome to Fight Multiple Sclerosis
Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK
Labiotech UG, All Rights Reserved -
Send this to friend